Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2019

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Doxorubicin 20 mg/m2

DRUG

Doxorubicin 30 mg/m2

DRUG

Best Standard of Care

Trial Locations (70)

1020

CHU Brugmann, Brussels

1082

Semmelweis Egyetem Radiológiai és Onkoterápiás Klinika, Budapest

1090

Medical University Vienna, Vienna

1097

Egyesített Szent István és Szent László Kórház - Rendelőintézet, Budapest

1200

UCL Saint-Luc, Brussels

4000

CHU Sart Tilman, Liège

4020

Krankenhaus der Elisabethinen Linz GmbH, Linz

4032

Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet, Debrecen

6720

Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged

13005

Hospital La Timone, Marseille

15212

Allegheny General Hospital, Pittsburgh

17033

Penn State Hershey Cancer Institute, Hershey

20122

Granda Osp. Magg. Policlinico, Milan

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

21079

Centre Jean-François Leclerc, Dijon

23006

Complejo Hospitalario de Jaen, Jaén

25000

Hospital Jean Minjoz, Besançon

28007

Hospital General Universario Gregorio Maranon, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

28100

A.O. Ospedale Maggiore della Carità, Novara

29010

Hospital Carlos Haya, Málaga

30120

Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia

32700

National Liver Institute / Menoufyia University, Menofia

33075

Hospital Saint André, Bordeaux

33081

Irccs Centro Di Riferimento Oncologico (Cro), Aviano

34295

Hospital Saint Eloi, Montpellier

35516

Medical Oncology department /Mansoura University Hospitals, Al Mansurah

38302

Centre hospitalier P Oudot, Bourgoin

38700

Hospital Grenoble, La Tronche

39008

Hospital Universitario Marques de Valdecilla, Santander

41124

Azienda Ospedaliera Policlinico di Modena, Modena

44093

Hospital Hotel Dieu, Nantes

44718

Gabrail Cancer Center, Canton

45067

Hospital La Source, Orléans

47012

Hospital Universitario Río Hortega, Valladolid

47014

IRST Istituto Romagnolo Ricerca e Cura dei Tumori, Meldola

47900

Rimini

48018

Ospedale Civile e degli Infermi, Faenza

54511

Hospital Brabois, Nancy

55041

Ausl 12 Livorno Ospedale Unico della Versilia, Lido di Camaiore

63003

Hospital Estaing, Clermont-Ferrand

66046

Hospital Saint Jean, Perpignan

67091

Hospital Civil, Strasbourg

69317

Hospital Croix Rousse, Lyon

75013

Hospital Pitié-Salpetriere, Paris

75020

Hospital Tenon, Paris

76031

CHU de Rouen- Hôpital Charles Nicolle, Rouen

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

80054

Hospital Amiens, Amiens

81675

Klinikum rechts der Isar der TU Munchen II, München

87042

CHU Dupuytren, Limoges

92110

Centre Hospitalier Beaujon, Clichy

94010

Hospital Henri-Mondor, Créteil

94804

Hospital Paul Brousse, Villejuif

Unknown

CHU UCL Mont-Godinne Dinant, Yvoir

Clinical Research Center/ Alexandria university hospital, Alexandria

Oncology Department, Medical Research Institute, Alexandria University, Alexandria

Medical Oncology department /Ain Shams University Hospitals, Cairo

National hepatology and tropical medicine research institute, Cairo

CHU, Dijon

CHU - Hôpital Archet, Nice

IC LOIRE, Saint-Etienne

Ain Wazein Hospital, El Chouf

Hacettepe University Medical Faculty, Ankara

Ege Univeristy Medical Faculty,, Izmir

06120

Universitätsklinikum Halle (Saale), Halle

04103

Universität Leipzig AöR, Leipzig

03010

Hospital General Universitario de Alicante, Alicante

07010

Hospital Universario Son Espaces, Palma de Mallorca

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY

NCT01655693 - Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter